CSPC Pharma's SYH2046 tablet gains US clinical trial approval
CSPC Pharmaceutical Group Limited (HKEX: 1093) announced that its SYH2046 tablets have been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S. The drug also secured approval from the National Medical Products Administration of the People's Republic of China for clinical trials to be conducted in China starting April 2025. Described as a first-in-class small molecule drug, SYH2046 is intended for treating heart failure following acute myocardial infarction. Preclinical data suggests that the drug can significantly improve cardiac function and reduce adverse cardiac remodeling in animal models. CSPC has submitted several patent applications for the treatment in both China and overseas.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when CSPC Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime